These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36613875)

  • 1. Design and Synthesis of Conformationally Flexible Scaffold as Bitopic Ligands for Potent D
    Kim HY; Lee JY; Hsieh CJ; Taylor M; Luedtke RR; Mach RH
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, in silico, and in vitro studies of novel dopamine D
    Elek M; Djokovic N; Frank A; Oljacic S; Zivkovic A; Nikolic K; Stark H
    Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000486. PubMed ID: 33615541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands.
    Mach RH; Huang Y; Freeman RA; Wu L; Vangveravong S; Luedtke RR
    Bioorg Med Chem Lett; 2004 Jan; 14(1):195-202. PubMed ID: 14684327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analogues of Arylamide Phenylpiperazine Ligands To Investigate the Factors Influencing D3 Dopamine Receptor Bitropic Binding and Receptor Subtype Selectivity.
    Hayatshahi HS; Xu K; Griffin SA; Taylor M; Mach RH; Liu J; Luedtke RR
    ACS Chem Neurosci; 2018 Dec; 9(12):2972-2983. PubMed ID: 30010318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
    Hidaka K; Tada S; Matsumoto M; Ohmori J; Tasaki Y; Nomura T; Usuda S; Yamaguchi T
    Br J Pharmacol; 1996 Apr; 117(8):1625-32. PubMed ID: 8732269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Substituted
    Lee B; Taylor M; Griffin SA; McInnis T; Sumien N; Mach RH; Luedtke RR
    Molecules; 2021 May; 26(11):. PubMed ID: 34073405
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis of bitopic ligands based on fallypride and evaluation of their affinity and selectivity towards dopamine D
    Tian GL; Hsieh CJ; Taylor M; Lee JY; Riad AA; Luedtke RR; Mach RH
    Eur J Med Chem; 2023 Dec; 261():115751. PubMed ID: 37688938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists.
    Furman CA; Roof RA; Moritz AE; Miller BN; Doyle TB; Free RB; Banala AK; Paul NM; Kumar V; Sibley CD; Newman AH; Sibley DR
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1448-61. PubMed ID: 25583363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of C9 alkoxy analogues of (-)-stepholidine as dopamine receptor ligands.
    Madapa S; Gadhiya S; Kurtzman T; Alberts IL; Ramsey S; Reith M; Harding WW
    Eur J Med Chem; 2017 Jan; 125():255-268. PubMed ID: 27688181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.
    Robarge MJ; Husbands SM; Kieltyka A; Brodbeck R; Thurkauf A; Newman AH
    J Med Chem; 2001 Sep; 44(19):3175-86. PubMed ID: 11543687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationships of naphthamides as dopamine D3 receptor ligands.
    Huang Y; Luedtke RR; Freeman RA; Wu L; Mach RH
    J Med Chem; 2001 May; 44(11):1815-26. PubMed ID: 11356115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
    Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and pharmacological evaluation of fluorine-containing D₃ dopamine receptor ligands.
    Tu Z; Li S; Cui J; Xu J; Taylor M; Ho D; Luedtke RR; Mach RH
    J Med Chem; 2011 Mar; 54(6):1555-64. PubMed ID: 21348515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
    Audinot V; Newman-Tancredi A; Gobert A; Rivet JM; Brocco M; Lejeune F; Gluck L; Desposte I; Bervoets K; Dekeyne A; Millan MJ
    J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.
    Luedtke RR; Mishra Y; Wang Q; Griffin SA; Bell-Horner C; Taylor M; Vangveravong S; Dillon GH; Huang RQ; Reichert DE; Mach RH
    ACS Chem Neurosci; 2012 Dec; 3(12):1050-62. PubMed ID: 23259040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramipexole derivatives as potent and selective dopamine D(3) receptor agonists with improved human microsomal stability.
    Chen J; Jiang C; Levant B; Li X; Zhao T; Wen B; Luo R; Sun D; Wang S
    ChemMedChem; 2014 Dec; 9(12):2653-60. PubMed ID: 25338762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.
    Rangel-Barajas C; Malik M; Taylor M; Neve KA; Mach RH; Luedtke RR
    J Neurochem; 2014 Nov; 131(4):418-31. PubMed ID: 25041389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-aminotetralin-derived substituted benzamides with mixed dopamine D2, D3, and serotonin 5-HT1A receptor binding properties: a novel class of potential atypical antipsychotic agents.
    Homan EJ; Copinga S; Elfström L; van der Veen T; Hallema JP; Mohell N; Unelius L; Johansson R; Wikström HV; Grol CJ
    Bioorg Med Chem; 1998 Nov; 6(11):2111-26. PubMed ID: 9881101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands.
    Ji M; Chen J; Ding K; Wu X; Varady J; Levant B; Wang S
    Bioorg Med Chem Lett; 2005 Mar; 15(6):1701-5. PubMed ID: 15745825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.